Human Metabolome Technologies (6090) · RiskRestated
Risk of Biomarker Patents Not Being Granted or Registered
First written in FY2017. 2 of 3 entries say "Restated". Latest entry: FY2020.
3entries
4years
0from disclosures
How it moved
Same theme, other companies
Risk of Losing IP Competitiveness Due to Failure to Obtain Patents, Obsolescence, Inability to Obtain Licenses, and InfringementA theme 108 companies write about · 108 as a headwind · 0 as a tailwind
The whole theme swung hardest in 2020: 4 of 43 companies on the "Worse" side.
64 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Showing 14 of the 108 companies compared. The sentences above are computed from all 108.Full recordFilings, disclosures and news, newest first
- FY2020RestatedAnnual report
「However, if patents relating to acquired biomarkers fail to be granted for any reason, it may become difficult to generate revenue from the biomarker business」
We continue to identify the risk that failure to obtain biomarker patents will make it difficult to monetise the business. - FY2019RestatedAnnual report
「If patents relating to acquired biomarkers fail to be granted, it may become difficult to generate revenue from the biomarker business」
We continue to identify the risk that failure to obtain biomarker patents will make it difficult to monetise the business. - FY2017First statedAnnual report
「If patents relating to acquired biomarkers fail to be granted for any reason, it may become difficult to generate revenue from the biomarker business, potentially affecting our group's business performance and future business development.」
The company assumes that securing intellectual property rights for biomarkers is a prerequisite for generating revenue and identifies the impact of failure to obtain patents as a risk.